Pharmaceutical Lifecycle Management Strategies in 2017 - Research and Markets
May 25 2017 - 4:39AM
Business Wire
Research and Markets has announced the addition of the
"Pharmaceutical Lifecycle Management Strategies in 2017" report to
their offering.
The report Pharmaceutical Lifecycle Management Strategies in
2017 provides a comprehensive assessment of product lifecycle (LCM)
management strategies that are being implemented by pharmaceutical
companies around the world.
Important challenges include pricing pressures, rising
development costs, stringent regulatory and reimbursement policies,
declining R&D productivity and drug patent cliffs (the
immediate decline in sales after the patent expiration).
These issues, particularly the productivity gap, leave
pharmaceutical companies exposed to generic and biosimilar
competition, which can erode a significant percentage of their
sales and market share within a short period of time. Companies
risk losing up to 90% of the revenue of some of their biggest
products to generic and biosimilar competition.
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Introduction to Pharmaceutical Lifecycle Management
Strategies
3.1 The Pharmaceutical Product Lifecycle Curve
3.2 Key Objectives of Life Cycle Management Strategies in
the
3.3 What is Driving the Need for Effective Lifecycle
Management
3.4 Classification and Benefits of Different Lifecycle
Management
3.5 Business Opportunities Created by LCM Strategies
3.6 Factors Impacting Choice of Lifecycle Strategies
4. Pharmaceutical Lifecycle Management - Commercial
Strategies
4.1 Rx-to-OTC Switch as an LCM Strategy
4.2 Geographical Expansion
4.3 Contract Research Organizations Helping Overcome Industry
Challenges
4.4 Pricing and Reimbursement Strategies for LCM in Pharma
4.5 Customer Retention Programs as LCM Strategies for Pharma
4.6 Asset Transactions as an LCM Tactic
5. Regulatory and Legal Strategies
5.1 Data Exclusivity
5.2 Orphan Drug Exclusivity
5.3 Pediatric exclusivity
6. Developmental Strategies
6.1 Introduction and Classification of Developmental
Strategies
6.2 Indication Expansion
6.3 Reformulation
6.4 Combination Drugs
7. Successful LCM Strategies Employed by Big Pharma: Case
Studies
7.1 Pfizer
7.2 AstraZeneca
7.3 Teva
7.4 AbbVie
7.5 Roche & GSK
7.6 Cipla
7.7 Unsuccessful Implementation of LCM Strategies: Case
Study
8. Patent Expiry Dates of Bestselling Pharmaceuticals
2005-2016
9. Life Cycle Management Strategies of Pipeline Products
2017
9.1 Eisai
9.2 Merck & Co
9.3 Johnson & Johnson
9.4 Takeda
9.5 AbbVie
10. Bibliography
For more information about this report visit
http://www.researchandmarkets.com/research/8g74cb/pharmaceutical
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170525005393/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Related Topics: Drug Discovery